ACTRN12615000094572已完成1 期
A Phase l/IIa, randomized, double blind, placebo-controlled, parallel group, pilot study to assess the safety and efficacy of a therapeutic HSV-2 DNA vaccine in HSV-2 positive adults
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- All
入选标准
- •Genital HSV-2 seropositive and genital HSV-1 seronegative
- •Generally healthy
- •No birthmarks, tattoos, wounds or skin conditions on either forearm
排除标准
- •Suffering acute or chronic disease
- •Pregant or nursing females
- •genital HSV-1, Hepatitis B or C, or HIV seropositive
- •Receiving medication known to have anti-HSV-2 activity
研究者
相似试验
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitisModerate to severe ulcerative colitisEUCTR2019-004090-50-ESONCOSTELLAE S.L.32
进行中（未招募）
1 期
Cannabidiol: a novel intervention for cannabis use problems?'Moderate cannabis use disorder' as defined by the diagnostic criteria in DSM-5 (published in May 2013), similar to the previous term 'cannabis dependence' (DSM-4).MedDRA version: 16.0Level: LLTClassification code 10007177Term: Cannabis dependenceSystem Organ Class: 100000004873EUCTR2013-000361-36-GBJoint Research Office82
招募中
1 期
A multiple-ascending dose study of RO7126209 in patients with prodromal or mild to moderate Alzheimer's diseaseAlzheimer's diseaseJPRN-jRCT2051230101uka Kulic MD210
撤回
2 期
A phase IIb, Double Blind, Randomized, placebo- controlled, Double-Dummy, Dose Rangining Study To Evaluate the Clinical Efficacy and Safety of Induction and Maintenance therapy with BMS- 945429 in subjects with Moderate to Severe Crohn's Disease.Crohns Diseaseinflamation1001796910027665NL-OMON37627Bristol-Myers Squibb12
进行中（未招募）
1 期
A clinical trial to assess the effect of PBF-680 in patients with moderate to severe Chronic Obstructive Pulmonar Disease on top of standard medication.Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD)MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2021-001732-25-ESPalobiofarma, S.102